Opendata, web and dolomites

NORVAS SIGNED

Therapeutic and Biomarker Potential of long non-coding RNAs in Vascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NORVAS project word cloud

Explore the words cloud of the NORVAS project. It provides you a very rough idea of what is the project "NORVAS" about.

acutely    survival    risk    samples    regulatory    extraordinary    cardiovascular    burden    ldlr    aortic    maintaining    contribution    eluting    ctps1    limit    expression    nudt6    rna    techniques    influences    as1    translational    natural    muscle    recognizing    inhibitors    experimental    molecular    mortality    aneurysm    forms    gene    mini    patients    transcripts    models    inhibition    efforts    stents    utilize    rodents    steadily    therapeutic    profiling    ones    nats    continues    vascular    ruptured    fibroblast    milieu    transcriptional    abdominal    morbidity    antisense    cell    vivo    uncovered    carotid    coding    fgf2    aneurysms    local    stroke    diseased    strategies    atherosclerotic    tissue    slfnl    society    predicting    modulators    rupture    plasma    subsequent    aging    mechanisms    multiple    diagnostic    rnas    post    etiology    regulators    human    vulnerability    groups    smooth    describes    launched    received    collective    progression    balloons    pigs    pathophysiological    homeostasis    micrornas    biomarker    plaque    transcriptomic    stenosis    drug    disease    functionally    feasibility    material   

Project "NORVAS" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.vascular-tum.de
 Total cost 1˙493˙125 €
 EC max contribution 1˙493˙125 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙493˙125.00
2    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 0.00

Map

 Project objective

The contribution of cardiovascular disease to human morbidity and mortality continues to steadily increase in our aging European society. In response, extraordinary efforts have been launched to determine the molecular and pathophysiological characteristics of its etiology. The collective work of multiple research groups has uncovered a complex transcriptional and post-transcriptional regulatory milieu, which is believed to be essential for maintaining cardiovascular homeostasis. Recently, non-coding RNAs, especially the ones with antisense capabilities such as microRNAs or ‘natural antisense transcripts’ (NATs) have received much attention. They have been identified as important transcriptional and post-transcriptional inhibitors of gene expression. This current proposal describes the development of novel diagnostic and therapeutic strategies to limit the burden of cardiovascular disease in general, and abdominal aortic aneurysms as well as carotid stenosis and subsequent stroke in particular. Using transcriptomic profiling techniques on human diseased tissue samples, we have identified two NATs (SLFNL-AS1 and NUDT6) as novel crucial regulators of smooth muscle cell survival via targeting CTPS1 and the fibroblast growth factor 2 (FGF2) in the vascular system. We are using disease-relevant experimental in vivo models (rodents and LDLR-/- mini-pigs) to functionally assess how inhibition of these two NATs influences aneurysm progression and atherosclerotic plaque vulnerability. One focus of our studies is to utilize local delivery mechanisms for non-coding RNA modulators, such as drug eluting balloons and stents, to enhance the translational feasibility of our findings. Furthermore, we have access to unique human plasma material from patients with early and advanced forms of aneurysm disease, enabling us to investigate the biomarker value of non-coding RNAs in recognizing patients with acutely ruptured aneurysms, as well as predicting the future risk of rupture.

 Publications

year authors and title journal last update
List of publications.
2018 Antonio Di Gennaro, Ana Carolina Araújo, Albert Busch, Hong Jin, Dick Wågsäter, Emina Vorkapic, Kenneth Caidahl, Per Eriksson, Bengt Samuelsson, Lars Maegdefessel, Jesper Z. Haeggström
Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm
published pages: 1907-1912, ISSN: 0027-8424, DOI: 10.1073/pnas.1717906115
Proceedings of the National Academy of Sciences 115/8 2019-05-10
2017 Nicholas J Leeper, Lars Maegdefessel
Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease
published pages: 611-621, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx249
Cardiovascular Research 114/4 2019-05-10
2019 Sandeep Kumar, Reinier A. Boon, Lars Maegdefessel, Stefanie Dimmeler, Hanjoong Jo
Role of Noncoding RNAs in the Pathogenesis of Abdominal Aortic Aneurysm
published pages: 619-630, ISSN: 0009-7330, DOI: 10.1161/circresaha.118.312438
Circulation Research 124/4 2019-05-10
2017 Yuhuang Li, Lars Maegdefessel
Non-coding RNA Contribution to Thoracic and Abdominal Aortic Aneurysm Disease Development and Progression
published pages: , ISSN: 1664-042X, DOI: 10.3389/fphys.2017.00429
Frontiers in Physiology 8 2019-05-10
2018 Daniel Y. Li, Albert Busch, Hong Jin, Ekaterina Chernogubova, Jaroslav Pelisek, Joakim Karlsson, Bengt Sennblad, Shengliang Liu, Shen Lao, Patrick Hofmann, Alexandra Bäcklund, Suzanne M. Eken, Joy Roy, Per Eriksson, Brian Dacken, Deepak Ramanujam, Anne Dueck, Stefan Engelhardt, Reinier A. Boon, Hans-Henning Eckstein, Joshua M. Spin, Philip S. Tsao, Lars Maegdefessel
H19 Induces Abdominal Aortic Aneurysm Development and Progression
published pages: 1551-1568, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.117.032184
Circulation 138/15 2019-05-10
2019 Suzanne M. Eken, Tinna Christersdottir, Greg Winski, Traimate Sangsuwan, Hong Jin, Ekaterina Chernogubova, John Pirault, Changyan Sun, Nancy Simon, Hanna Winter, Alexandra Backlund, Siamak Haghdoost, Göran K. Hansson, Martin Halle, Lars Maegdefessel
miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease
published pages: 72-82, ISSN: 2452-302X, DOI: 10.1016/j.jacbts.2018.10.006
JACC: Basic to Translational Science 4/1 2019-05-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORVAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORVAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

NanoBeam (2019)

Quantum Coherent Control: Self–Interference of Electron Beams with Nanostructures

Read More  

DNACom (2019)

Compartmentalized DNA Computers for In-Vitro Diagnostic Applications

Read More